STOCK TITAN
  1. Home
  2. News
  3. EKSO

Ekso Bionics Holdings Inc - EKSO STOCK NEWS

Welcome to our dedicated news page for Ekso Bionics Holdings (Ticker: EKSO), a resource for investors and traders seeking the latest updates and insights on Ekso Bionics Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ekso Bionics Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ekso Bionics Holdings's position in the market.

News
Ekso Bionics to Report First Quarter 2024 Financial Results on April 29, 2024
Rhea-AI Summary
Ekso Bionics, a leader in exoskeleton technology for medical and industrial use, will report its first quarter 2024 financial results on April 29, 2024. The Company will discuss financial results and recent business developments in a conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
conferences earnings
-
News
Ekso Bionics Receives Final Payment Determination for Medicare Reimbursement from the Centers for Medicare & Medicaid Services (CMS) for Ekso Indego Personal
Rhea-AI Summary
Ekso Bionics Holdings, Inc. announces Medicare reimbursement for Ekso Indego Personal at $91,031.93, effective April 1, 2024. The Healthcare Common Procedure Coding System Code K1007 approved for billing. Ekso Bionics to collaborate with clinics for patient qualification and training.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
none
-
News
Ekso Bionics Reports Record Annual Revenue of $18.3 Million
Rhea-AI Summary
Ekso Bionics Holdings, Inc. reported record revenue of $18.3 million in 2023, a 42% year-over-year increase. The Company sold 151 EksoHealth units and launched GaitCoach software. Despite a net loss of $15.2 million for the full year, Ekso remains optimistic about long-term growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.76%
Tags
none
News
Ekso Bionics to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
Rhea-AI Summary
Ekso Bionics Holdings, Inc. (EKSO) will release financial and business results for Q4 and full year 2023 on March 4, 2024. The Company, known for exoskeleton technology, will host a conference call to discuss the results and recent developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
conferences earnings
-
News
Ekso Bionics Announces $4.6 Million Registered Direct Offering
Rhea-AI Summary
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced a securities purchase agreement with institutional investors for the purchase and sale of 2,967,742 shares of common stock at a purchase price of $1.55 per share, resulting in total gross proceeds of approximately $4.6 million before deducting expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.19%
Tags
offering
-
News
Ekso Bionics Launches GaitCoach Software for EksoNR
Rhea-AI Summary
Ekso Bionics Holdings, an industry leader in exoskeleton technology for medical and industrial use, announced the launch of GaitCoach™, its next generation gait therapy software for EksoNR. GaitCoach is designed to improve user trust in technology, provide impactful feedback, and offer specific guidance, making the device more intuitive and easier to use for both patients and physical therapists. The software has received positive feedback from experienced users, with 96% finding it intuitive and 93% believing it would be useful for new or less experienced therapists. However, the software is initially available only in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15%
Tags
none
News
Ekso Bionics Reports Certain Preliminary Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced preliminary top line financial results for the fourth quarter and fiscal year ended December 31, 2023. Total revenue for Q4 2023 is estimated to be in the range of $4.7 million to $4.9 million, compared to $3.6 million in Q4 2022. Total revenue for fiscal year 2023 is estimated to be in the range of $18.1 million to $18.3 million, compared to $12.9 million in 2022. Estimated cash as of December 31, 2023, was $8.6 million, compared to $20.5 million at December 31, 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.8%
Tags
earnings
-
News
Ekso Bionics Receives CMS Coding Approval for Ekso Indego Personal
Rhea-AI Summary
Ekso Bionics Holdings, an industry leader in exoskeleton technology for medical and industrial use, announced that the Centers for Medicare & Medicaid Services has approved the use of Healthcare Common Procedure Coding System Code K1007 for billing Medicare for their Ekso Indego Personal device. The proposed payment level is $94,617, expected to take effect on April 1, 2024. This milestone is expected to substantially lower the cost of the device for eligible individuals with spinal cord injuries, improving health outcomes and enhancing quality of life.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
none
-
News
Ekso Bionics to Participate at Centers for Medicare & Medicaid Services (CMS) Second Biannual 2023 Healthcare Common Procedure Coding System (HCPCS) Public Meeting on Wednesday, November 29
Rhea-AI Summary
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced its participation at the CMS HCPCS public meeting to discuss Medicare payment for Ekso Indego Personal, aiming to provide thousands of individuals with spinal cord injuries access to their exoskeleton technology. The company submitted a coding verification request for reimbursement claims and expects a determination soon. The CMS' final rule published on November 1, 2023, will classify certain exoskeleton-type devices as braces for Medicare payment purposes, with any national payment amount established from the meeting effective April 1, 2024. Ekso Indego Personal is a modular, lightweight exoskeleton, offering advanced gait modes for increased walking speeds and independence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
conferences
News
Centers for Medicare & Medicaid Services (CMS) Codifies Medicare Coverage for Ekso Indego Personal
Rhea-AI Summary
Ekso Bionics Holdings, Inc. announces that the Centers for Medicare & Medicaid Services (CMS) has finalized its 2024 Home Health Rule, which includes exoskeletons in the Medicare brace benefit category. This ruling could significantly expand the market for Ekso Indego Personal, a modular and portable exoskeleton that provides increased mobility for individuals with spinal cord injuries. The ruling will go into effect on January 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.65%
Tags
none
Stock EKSO logo
Ekso Bionics Holdings Inc

Nasdaq:EKSO

EKSO Rankings

#5089 Ranked by Market Cap
#4704 Ranked by Stock Gains
N/A Ranked by Dividends

EKSO Stock Data

25.06M
16.01M
13.5%
7.68%
0.75%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Richmond

About EKSO

since 2005, ekso bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. the company’s first commercially available product called ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. by designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, ekso bionics is helping people rethink current physical limitations and achieve the remarkable. ekso bionics is headquartered in richmond, california international offices: europe/middle east/africa 29th floor one canada square canary wharf london, united kingdom +44 20 7060 3568 kunden service deutschland +49 89 55067774